Investor Relations
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 18, 2023
-
Aug 2, 2022
-
Dec 22, 2021Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization
-
Nov 11, 2021Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38
-
Nov 4, 2021Company's validated test available in the UK following implementation of UKHSA CTDA Regulations
-
Sep 27, 2021In addition to hosting a booth to promote its existing diagnostics products at the conference, the Company will also hold a press conference to introduce its upcoming at-home and point-of-care PCR device
-
Sep 13, 2021Company CEO and CFO will also be conducting a presentation that will be available on-demand
-
Sep 8, 2021Peer-reviewed results describe the Company's test being used to confirm the presence of the virus on community waste, including mutated strains
-
Aug 12, 2021Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33
-
May 13, 2021Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26
-
Apr 28, 2021Times of India article highlights CoSara's tireless efforts to increase manufacturing of COVID-19 tests in response to deadly wave of infections
-
Apr 20, 2021Paper published in the Journal of Medical Microbiology utilizes Company's test in rapidly deployable mobile molecular diagnostics
-
Mar 25, 2021Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million
-
Mar 2, 2021Proprietary platform includes countertop device being developed for Co-Diagnostics by world experts in rapid PCR